Home/Filings/4/0001415889-25-003062
4//SEC Filing

Cline Christopher R. 4

Accession 0001415889-25-003062

CIK 0001438533other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 8:30 PM ET

Size

9.5 KB

Accession

0001415889-25-003062

Insider Transaction Report

Form 4
Period: 2025-01-31
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Employee stock option (right to buy)

    2025-01-31+58,00058,000 total
    Exercise: $20.46Exp: 2035-01-31Common Stock (58,000 underlying)
  • Award

    Common Stock

    2025-01-31+21,50095,230 total
  • Sale

    Common Stock

    2025-02-03$20.12/sh5,192$104,46390,038 total
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
  • [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
  • [F3]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Issuer

Travere Therapeutics, Inc.

CIK 0001438533

Entity typeother

Related Parties

1
  • filerCIK 0001943192

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 8:30 PM ET
Size
9.5 KB